DSC Advisors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

DSC Advisors’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-1,071	Closed	-$677K	–	90
2015 Q2	$677K	Hold	1,071	–	–	0.35%	42
2015 Q1	$551K	Hold	1,071	–	–	0.29%	48
2014 Q4	$574K	Buy	1,071 +238	+29%	+$107K	0.33%	47
2014 Q3	$1.25M	Hold	833	–	–	0.63%	35
2014 Q2	$1.14M	Buy	+833	New	+$966K	0.61%	29

Other funds holding VIRX

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

DSC Advisors's VIRX Position: Q3 2015 in Review

DSC Advisors sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2015, closing a stake of 1,071 shares — an estimated $677K sold.

DSC Advisors first reported a position in VIRX in Q2 2014 and held it in 5 quarters. The position peaked at $1.25M in Q3 2014. 59 funds tracked by Wall St. Rank hold VIRX as of Q3 2015.

DSC Advisors reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2015 after selling out during the quarter.
DSC Advisors sold 1,071 Viracta Therapeutics, Inc. Common Stock shares in Q3 2015, an estimated $677K.
DSC Advisors first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2014 and held it in 5 quarters.
DSC Advisors's Viracta Therapeutics, Inc. Common Stock position peaked at $1.25M in Q3 2014.
59 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2015.

Based on DSC Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.